Agenus (AGEN) 10-Q 4 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015
Entity Registrant Name	AGENUS INC
Entity Central Index Key	1,098,972
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		84,646,215

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
ASSETS
Cash and cash equivalents	$ 184,138,960	$ 25,714,519
Short-term investments	14,993,700	14,509,570
Inventories	88,200	95,700
Accounts Receivable	7,331,624	463,007
Prepaid expenses	1,953,486	1,247,548
Other current assets	437,311	639,957
Total current assets	208,943,281	42,670,301
Plant and equipment, net of accumulated amortization and depreciation of $29,351,331 and $28,369,982 at September 30, 2015 and December 31, 2014, respectively	7,829,693	5,996,687
Goodwill	18,139,991	17,869,023
Acquired intangible assets, net of accumulated amortization of $873,667 and $462,248 at September 30, 2015 and December 31, 2014, respectively	6,490,481	6,773,722
Other long-term assets	1,204,804	1,216,795
Total assets	242,608,250	74,526,528
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current portion, long-term debt	146,061	1,257,178
Current portion, deferred revenue	5,967,198	184,421
Accounts payable	3,091,199	1,710,946
Accrued liabilities	13,738,916	5,501,527
Other current liabilities	5,342,496	575,351
Total current liabilities	28,285,870	9,229,423
Long-term debt	110,553,452	4,769,359
Deferred revenue	15,498,207	3,009,568
Contingent royalty obligation		15,279,000
Contingent purchase price consideration	3,747,000	16,420,300
Other long-term liabilities	$ 7,547,617	$ 2,800,491
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Common stock, par value $0.01 per share; 140,000,000 shares authorized; 84,646,215 and 62,720,065 shares issued at September 30, 2015 and December 31, 2014, respectively	$ 846,462	$ 627,201
Additional paid-in capital	841,041,405	715,667,633
Accumulated other comprehensive loss	(1,331,638)	(1,970,420)
Accumulated deficit	(763,580,441)	(691,306,343)
Total stockholders’ equity	76,976,104	23,018,387
Total liabilities and stockholders’ equity	242,608,250	74,526,528
Series A-1 convertible preferred stock [Member]
STOCKHOLDERS’ EQUITY
Preferred stock, par value $0.01 per share; 5,000,000 shares authorized: Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at September 30, 2015 and December 31, 2014; liquidation value of [$32,113,792] at September 30, 2015	$ 316	$ 316

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Plant and equipment, accumulated amortization and depreciation	$ 29,351,331	$ 28,369,982
Acquired intangible assets, accumulated amortization	$ 873,667	$ 462,248
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	140,000,000	140,000,000
Common stock, shares issued	84,646,215	62,720,065
Series A-1 convertible preferred stock [Member]
Series A-1 convertible preferred stock, shares designated	31,620	31,620
Series A-1 convertible preferred stock, shares issued	31,620	31,620
Series A-1 convertible preferred stock, shares outstanding	31,620	31,620
Series A-1 convertible preferred stock, liquidation value	$ 32,164,572

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Research and development revenue	$ 6,848,194	$ 1,563,378	$ 17,178,191	$ 5,358,322
Total revenues	6,848,194	1,563,378	17,178,191	5,358,322
Operating expenses:
Research and development	(18,502,063)	(5,284,607)	(52,495,316)	(14,979,844)
General and administrative	(6,407,902)	(4,919,675)	(19,910,650)	(16,209,790)
Contingent purchase price consideration fair value adjustment	6,994,000	969,000	(7,326,700)	(164,000)
Operating loss	(11,067,771)	(7,671,904)	(62,554,475)	(25,995,312)
Other (expense) income:
Non-operating (expense) income	(653,376)	(127,367)	(7,356,139)	10,449,462
Interest expense, net	(1,401,102)	(310,080)	(2,363,484)	(962,015)
Net loss	(13,122,249)	(8,109,351)	(72,274,098)	(16,507,865)
Dividends on Series A-1 convertible preferred stock	(50,780)	(51,159)	(152,099)	(153,292)
Net loss attributable to common stockholders	$ (13,173,029)	$ (8,160,510)	$ (72,426,197)	$ (16,661,157)
Per common share data:
Basic and diluted net loss attributable to common stockholders	$ (0.16)	$ (0.13)	$ (0.95)	$ (0.28)
Weighted average number of common shares outstanding:
Basic and diluted	84,569,118	62,831,541	75,935,985	58,710,338
Other comprehensive income (loss):
Foreign currency translation gain (loss)	$ (680,993)	$ (1,294,720)	$ 625,132	$ (1,161,036)
Unrealized gain on investments	7,760	1,863	13,650	3,816
Other comprehensive income (loss)	(673,233)	(1,292,857)	638,782	(1,157,220)
Comprehensive loss	$ (13,846,262)	$ (9,453,367)	$ (71,787,415)	$ (17,818,377)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (72,274,098)	$ (16,507,865)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,403,324	1,019,073
Share-based compensation	5,218,479	3,700,518
Non-cash interest expense	1,643,417	461,653
Loss on disposal of assets	0	1,150
Change in fair value of contingent obligations	14,190,000	(10,652,557)
In-process research and development purchase	12,245,230	0
Loss on extinguishment of debt	154,117	0
Change in fair value of assumed convertible notes	0	(205,143)
Changes in operating assets and liabilities:
Accounts receivable	(7,232,669)	1,200
Inventories	7,500	(95,700)
Prepaid expenses	(693,981)	(425,485)
Accounts payable	1,266,219	35,207
Deferred revenue	18,465,694	(2,695,737)
Accrued liabilities and other current liabilities	8,390,007	(2,021,879)
Other operating assets and liabilities	(10,367,586)	(341,034)
Net cash used in operating activities	(27,584,347)	(27,726,599)
Cash flows from investing activities:
Cash acquired in acquisition	0	514,470
Purchases of plant and equipment	(2,818,429)	(1,105,472)
Purchases of available-for-sale securities	(15,006,730)	(14,517,644)
Proceeds from sale of available-for-sale securities	14,534,486	0
Net cash used in investing activities	(3,290,673)	(15,108,646)
Cash flows from financing activities:
Net proceeds from sale of equity	109,669,980	56,792,252
Proceeds from employee stock purchases and option exercises	1,963,738	150,140
Financing of plant and equipment	0	(39,156)
Proceeds from issuance of long-term debt	109,000,000	0
Debt issuance costs	1,774,323	0
Payments of debt	(1,111,112)	(2,500,000)
Payment of contingent purchase price consideration	(8,380,483)	0
Payment of preferred stock dividends	0	(460,963)
Payment of contingent royalty obligation	(20,000,000)	(400,000)
Net cash provided by financing activities	189,367,800	53,542,273
Effect of exchange rate changes on cash	(68,339)	327,128
Net increase in cash and cash equivalents	158,424,441	11,034,156
Cash and cash equivalents, beginning of period	25,714,519	27,351,969
Cash and cash equivalents, end of period	184,138,960	38,386,125
Supplemental cash flow information:
Cash paid for interest	770,538	531,863
Supplemental disclosures - non-cash activities:
Purchases of plant and equipment in accounts payable and accrued liabilities	111,903	292,106
Contingent purchase price consideration issued in connection with the acquisition of 4-Antibody AG	0	9,721,000
Issuance of common stock, $0.01 par value, as payment of long-term debt	0	953,765
Contingent royalty consideration [Member]
Supplemental disclosures - non-cash activities:
Issuance of common stock	2,142,000	0
Contingent purchase price obligation [Member]
Supplemental disclosures - non-cash activities:
Issuance of common stock	344,550	0
SECANT Yeast Display technology [Member]
Supplemental disclosures - non-cash activities:
Issuance of common stock	3,000,000	0
4-antibody acquisition [Member]
Supplemental disclosures - non-cash activities:
Issuance of common stock	$ 0	$ 10,102,259

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Parenthetical) - $ / shares	Sep. 30, 2015	Sep. 30, 2014
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Contingent royalty consideration [Member]
Common Stock, Par or Stated Value Per Share	0.01
Contingent purchase price obligation [Member]
Common Stock, Par or Stated Value Per Share	0.01
SECANT Yeast Display technology [Member]
Common Stock, Par or Stated Value Per Share	$ 0.01
4-antibody acquisition [Member]
Common Stock, Par or Stated Value Per Share		$ 0.01

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2015
Description Of Business [Abstract]
Business, Liquidity And Basis Of Presentation	Note A - Business, Liquidity and Basis of Presentation Agenus Inc. (including its subsidiaries, also referred to as “Agenus,” the “Company,” “we,” “us,” and “our”) is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. Our approaches are driven by three platform technologies: · our antibody platforms, including our proprietary Retrocyte Display™, SECANT ® · our heat shock protein (HSP)-based vaccines; and · our saponin-based vaccine adjuvants, principally our QS-21 Stimulon ® We have a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, our Prophage vaccine, a HSP-based autologous vaccine candidate for glioblastoma multiforme, or GBM, a form of brain cancer, and a number of advanced QS-21 Stimulon-containing vaccine candidates in late stage development by our partner, GlaxoSmithKline plc (GSK). For the treatment of cancer, our programs aim to stimulate the immune system to recognize and eradicate cancer cells and disable the mechanisms that cancer cells employ to evade detection and destruction by the immune system. Because of the breadth of our portfolio, we have the ability to combine our proprietary vaccines with a portfolio of checkpoint modulating antibodies against major checkpoint targets to explore and optimize cancer treatments. Our strategy is to develop these agents either alone or in combinations to yield best-in-class treatments. We assess the development, commercialization and/or partnering strategies with respect to each of our internal product candidates periodically based on several factors, including clinical trial results, competitive positioning and funding requirements and resources. Agenus’ core technologies include Retrocyte Display, a powerful proprietary platform designed to effectively discover and optimize novel, fully human and humanized monoclonal antibodies against antigens of interest. Our Retrocyte Display technology is applied to the discovery and development of antibodies, including those targeting significant checkpoint targets. Agenus and its partners currently have pre-clinical programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed check-point programs. In April 2015, we expanded our antibody discovery platform through the acquisition of key antibody assets from Celexion, LLC (Celexion); see Note L. Among the acquired assets was the SECANT yeast display platform for the generation of novel monoclonal antibodies and efficient integration of drug targets such as CPMs. On January 9, 2015 and effective February 19, 2015, we entered into a broad, global alliance with Incyte Corporation and a wholly-owned subsidiary thereof (collectively "Incyte") to pursue the discovery and development of CPMs, initially targeting GITR, OX40, TIM-3 and LAG-3 in the fields of hematology and oncology. We also began collaborating with Merck Sharp & Dohme Corp in April 2014 to discover antibodies against two undisclosed CPM targets. We anticipate initiating clinical trials with the first of our CPM antibody candidates in 2016. We have also been advancing a series of HSP-based vaccines to treat cancer and infectious disease. In June 2015, at the American Society of Clinical Oncology (ASCO) meeting, we reported positive results from a Phase 2 clinical trial with our Prophage vaccine, which showed that patients with newly-diagnosed GBM who were treated with a combination of our Prophage vaccine and standard of care showed substantial improvement both in progression-free survival and median overall survival, as compared to historical control data. The most significant clinical improvements were seen in patients with less elevated PD-L1 expression in peripheral blood monocytes. These observations suggested that while some patients may derive the greatest benefit from standard of care and the Prophage vaccine alone, patients with more elevated PD-L1 expression on peripheral monocytes may benefit from a combination of Prophage in addition to checkpoint modulators PD-1 or PD-L1. We are currently exploring advancing our Prophage vaccine into well-controlled randomized trials designed to study Prophage versus the standard of care. In addition, efforts are currently underway to conduct adequately controlled and randomized combination studies using Prophage while we simultaneously explore partnership opportunities to license Prophage. In 2014, we also reported positive results from a Phase 2 clinical trial with our HerpV vaccine candidate for genital herpes, and while we do not expect to advance into a Phase 3 clinical trial for genital herpes, we are currently in the process of evaluating the broader application of our HSP peptide-based vaccines. The Company’s QS-21 Stimulon adjuvant is a key component in several of GSK’s pre-clinical and clinical stage vaccine programs, which target prophylactic or therapeutic impact in a variety of infectious diseases and cancer. In December 2014, GSK reported that its Phase 3 clinical trial with shingles vaccine candidate, HZ/su, using our QS-21 Stimulon adjuvant, met its primary endpoint, reducing the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo. GSK also reported positive Phase 3 clinical trial results in October 2013 for its malaria vaccine candidate using QS-21 Stimulon, Mosquirix™ (RTS,S), which recently received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency. In September 2015, we monetized a portion of the future royalties we are contractually entitled to receive from GSK from sales of its shingles and malaria vaccines through a Note Purchase Agreement and received net proceeds of approximately $98.2 million; refer to Note E for additional information. QS-21 Stimulon is also the subject of an out-license agreement with Janssen Sciences Ireland Uc for use in a vaccine for Alzheimer’s disease. Our business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of our collaborations. Our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. Part of our strategy is to develop and commercialize some of our product candidates by continuing our existing arrangements with academic and corporate collaborators and licensees and by entering into new collaborations. We have incurred significant losses since our inception. As of September 30, 2015, we had an accumulated deficit of $763.6 million. To date, we have financed our operations primarily through the sale of equity and debt securities. We believe that, based on our current plans and activities, our working capital resources at September 30, 2015 will be sufficient to satisfy our liquidity requirements into the first half of 2018. We may attempt to raise additional funds by: (1) pursuing collaboration, out-licensing and/or partnering opportunities for our portfolio programs and product candidates with one or more third parties, (2) renegotiating third party agreements, (3) selling assets, (4) securing additional debt financing and/or (5) selling equity securities. Satisfying long-term liquidity needs may require the successful commercialization and/or substantial out-licensing or partnering arrangements for our antibody discovery platforms, CPM antibody programs, HSP-based vaccines, and vaccines containing QS-21 Stimulon under development by our licensees. Our long-term success will also be dependent on the successful identification, development and commercialization of potential other product candidates, each of which will require additional capital with no certainty of timing or probability of success. If we incur operating losses for longer than we expect and/or we are unable to raise additional capital, we may become insolvent and be unable to continue our operations. Our research and development program costs include compensation and other direct costs plus an allocation of indirect costs, based on certain assumptions, and our review of the status of each program. Our product candidates are in various stages of research and development and significant additional expenditures will be required if we start new clinical trials, encounter delays in our programs, apply for regulatory approvals, continue development of our technologies, expand our operations, and/or bring our product candidates to market. The eventual total cost of each clinical trial is dependent on a number of factors such as trial design, length of the trial, number of clinical sites, number of patients, and trial sponsorship. The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive, and uncertain. Because our CPM antibody programs are pre-clinical and the further development of our HSP-based vaccines is subject to evaluation and uncertainty, we are unable to reliably estimate the cost of completing our research and development programs or the timing for bringing such programs to various markets or substantial partnering or out-licensing arrangements. Therefore, we cannot predict if or when material cash inflows from operating activities are likely to commence. We will continue to adjust other spending as needed in order to preserve liquidity. Active programs involving QS-21 Stimulon depend on our collaboration partners or licensees successfully completing clinical trials, successfully manufacturing QS-21 Stimulon to meet demand, obtaining regulatory approvals and successfully commercializing product candidates containing QS-21 Stimulon. The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete annual consolidated financial statements. In the opinion of our management, the condensed consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of our financial position and operating results. All significant intercompany transactions and accounts have been eliminated in consolidation. Certain reclassifications have been made to previously reported amounts to conform to the current presentation. Operating results for the nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. For further information, refer to our consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (the “SEC”). For our foreign subsidiaries the local currency is the functional currency. Assets and liabilities of our foreign subsidiaries are translated into U.S. dollars using rates in effect at the balance sheet date while revenues and expenses are translated into U.S. dollars using average exchange rates during the period. The cumulative translation adjustment resulting from changes in exchange rates are included in the consolidated balance sheets as a component of accumulated other comprehensive loss in total stockholders’ equity. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	Note B - Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our Directors’ Deferred Compensation Plan, or DDCP). Diluted net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding (including common shares issuable under our DDCP) plus the dilutive effect of outstanding instruments such as warrants, stock options, nonvested shares, and convertible preferred stock. Because we reported a net loss attributable to common stockholders for all periods presented, diluted net loss per common share is the same as basic net loss per common share, as the effect of utilizing the fully diluted share count would have reduced the net loss per common share. Therefore, the following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding because they would be anti-dilutive: Nine months ended September 30, 2015 2014 Warrants 4,351,450 2,951,450 Stock options 8,226,791 6,841,400 Nonvested shares 1,734,821 78,828 Convertible preferred stock 333,333 333,333

Investments

Investments	9 Months Ended
	Sep. 30, 2015
Investments [Abstract]
Cash, Cash Equivalents, and Short-term Investments	Note C - Investments Cash equivalents and short-term investments consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Cost Estimated Fair Value Cost Estimated Fair Value Institutional Money Market Funds $ 172,811 $ 172,811 $ 25,149 $ 25,149 U.S. Treasury Bills 14,971 14,994 14,508 14,510 Total $ 187,782 $ 187,805 $ 39,657 $ 39,659 For the nine months ended September 30, 2015, we received proceeds of approximately $14.5 million from the sale of available-for-sale securities. No proceeds from the maturity of available-for-sale securities were received for the year ended December 31, 2014. Gross realized gains included in net loss as a result of the sale of available-for-sale securities were immaterial for the nine months ended September 30, 2015. As a result of the short-term nature of our investments, there were minimal unrealized holding gains or losses as of September 30, 2015 and December 31, 2014. Of the investments listed above, $172.8 million and $25.1 million have been classified as cash equivalents and $15.0 million and $14.5 million as short-term investments on our condensed consolidated balance sheet as of September 30, 2015 and December 31, 2014, respectively.

Goodwill and Acquired Intangibl

Goodwill and Acquired Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Acquired Intangible Assets	Note D - Goodwill and Acquired Intangible Assets The following table sets forth the changes in the carrying amount of goodwill for the nine months ended September 30, 2015 (in thousands): Balance, December 31, 2014 $ 17,869 Foreign currency translation adjustment 271 Balance, September 30, 2015 $ 18,140 Acquired intangible assets consisted of the following at September 30, 2015 (in thousands): Amortization (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual Property 15 years $ 4,425 $ (479 ) $ 3,946 Trademarks 4.5 years 829 (300 ) 529 Other 3 years 175 (95 ) 80 In-process research and development Indefinite 1,935 — 1,935 Total $ 7,364 $ (874 ) $ 6,490 The weighted average amortization period of our finite-lived intangible assets is 13 years. Amortization expense related to acquired intangibles is estimated at $134,000 for the remainder of 2015, $512,000 for each of the years ending 2016 and 2017, $410,000 for the year ending 2018, $295,000 for the year ending 2019, and $299,000 for each of the years ending 2020-2029. The acquired in-process research and development ("IPR&D") asset relates to the pre-clinical CPM antibody programs acquired with our acquisition of 4-Antibody AG (“4-AB”) 4-AB in February 2014. IPR&D acquired in a business combination is capitalized at fair value until the underlying project is completed and is subject to impairment testing at least annually. Once the project is completed, the carrying value of IPR&D is amortized over the estimated useful life of the asset. Post-acquisition research and development expenses related to the acquired IPR&D are expensed as incurred.

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt	Note E - Debt Debt obligations consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): Debt instrument Principal at September 30, 2015 Non-cash Interest Unamortized Debt Issuance Costs Unamortized Debt Discount Balance at September 30, 2015 Current Portion: Debentures $ 146 $ — $ — $ — $ 146 Long-term Portion: 2015 Subordinated Notes 14,000 — — (2,510 ) 11,490 Note Purchase Agreement 100,000 825 (1,514 ) (248 ) 99,063 Total long-term $ 114,000 $ 825 $ (1,514 ) $ (2,758 ) $ 110,553 Total $ 114,146 $ 825 $ (1,514 ) $ (2,758 ) $ 110,699 Debt instrument Principal at December 31, 2014 Non-cash Interest Unamortized Debt Issuance Costs Unamortized Debt Discount Balance at December 31, 2014 Current Portion: Debentures $ 146 $ — $ — $ — $ 146 SVB Loan 1,111 — — — 1,111 Total current $ 1,257 $ — $ — $ — $ 1,257 Long-term Portion: 2013 Notes 5,000 — — (231 ) 4,769 Total $ 6,257 $ — $ — $ (231 ) $ 6,026 Subordinated Notes On February 20, 2015, we, certain existing investors and certain additional investors entered into an Amended and Restated Note Purchase Agreement, pursuant to which we (i) canceled our senior subordinated promissory notes issued in April 2013 (the "2013 Notes") in exchange for new senior subordinated promissory notes (the “2015 Subordinated Notes”) in the aggregate principal amount of $5.0 million, (ii) issued additional 2015 Subordinated Notes in the aggregate principal amount of $9.0 million and (iii) issued five year warrants to purchase 1,400,000 shares of our common stock at an exercise price of $5.10 per share. The 2015 Subordinated Notes bear interest at a rate of 8% per annum, payable in cash on the first day of each month in arrears. Among other default and acceleration terms customary for indebtedness of this type, the 2015 Subordinated Notes include default provisions which allow for the noteholders to accelerate the principal payment of the 2015 Subordinated Notes in the event we become involved in certain bankruptcy proceedings, become insolvent, fail to make a payment of principal or (after a grace period) interest on the 2015 Subordinated Notes, default on other indebtedness with an aggregate principal balance of $13.5 million or more if such default has the effect of accelerating the maturity of such indebtedness, or become subject to a legal judgment or similar order for the payment of money in an amount greater than $13.5 million if such amount will not be covered by third-party insurance. The 2015 Subordinated Notes are not convertible into shares of our common stock and will mature on February 20, 2018, at which point we must repay the outstanding balance in cash. The Company may prepay the 2015 Subordinated Notes at any time, in part or in full, without premium or penalty. The exchange of the 2013 Notes for the 2015 Subordinated Notes was accounted for as a debt extinguishment under the guidance of Accounting Standards Codification (ASC) 470-50 Debt: Modifications and Extinguishments. Note Purchase Agreement Related to Sale of Future Royalties On September 4, 2015, we and our wholly-owned subsidiaries, Antigenics LLC (“Antigenics”) and Aronex Pharmaceuticals, Inc. (“Aronex”), entered into a Note Purchase Agreement (the “NPA”) with Oberland Capital SA Zermatt LLC, as collateral agent (“Oberland”), an affiliate of Oberland as the lead purchaser and other purchasers. Pursuant to the terms of the NPA, on September 8, 2015 (the “Closing Date”), Antigenics issued $100.0 million aggregate principal amount of limited recourse notes (the “Notes”) to the purchasers. Antigenics has the option to issue an additional $15.0 million aggregate principal amount of Notes (the “Additional Notes”) to the purchasers within 15 days after approval of GSK’s shingles vaccine, HZ/su, by the Food and Drug Administration, provided such approval occurs on or before June 30, 2018. The Notes accrue interest at a rate of 13.5% per annum, compounded quarterly, from and after the Closing Date computed on the basis of a 360-day year and the actual number of days elapsed. Principal and interest payments are due on each of March 15, June 15, September 15 and December 15, and shall be made solely from the royalties paid from GSK to Antigenics on sales of GSK’s shingles and malaria vaccines. The Notes are limited recourse and secured solely by a first priority security interest in the royalties and accounts and payment intangibles relating thereto plus various rights of Antigenics related to the royalties under its contracts with GSK (the “Collateral”). GSK will send all royalty payments to a segregated bank account, and to the extent there are insufficient royalties deposited into the account to fund a quarterly interest payment, the interest will be capitalized and added to the aggregate principal balance of the loan. The final legal maturity date of the Notes is the earlier of (i) the 10 th At our option, we may redeem all, but not less than all, of the Notes at any time prior to the Maturity Date. The redemption price is equal to the outstanding principal amount of the Notes, plus all accrued and unpaid interest thereon, plus a premium payment that would yield an aggregate internal rate of return (“IRR”) for the purchasers as follows: (i) an IRR of 20% if the redemption occurs within 24 months of the Closing Date, (ii) an IRR of 17.5% if the redemption occurs after 24 months but within 48 months of the Closing Date, and (iii) an IRR of 15% if the redemption occurs more than 48 months after the Closing Date (the “Redemption Payment”). On September 8, 2018, each purchaser has the option to require Antigenics to repurchase up to 15% of the Notes issued to such purchaser on the Closing Date (the “Put Notes”) at a purchase price equal to the principal amount thereof plus accrued and unpaid interest thereon (the “Put Payment”). Antigenics is required to complete any such repurchase within 90 days after September 8, 2018. On the earlier of (i) September 8, 2027 and (ii) the Maturity Date, Antigenics is required to pay the purchasers an amount equal to the following (the “Make-Whole Payment”): $100.0 million (or $115.0 million if the Additional Notes are sold) minus the aggregate amount of all payments made in respect of the Notes (regardless of whether characterized as principal or interest at the time of payment), including the original principal amount of any repaid Put Notes. The NPA specifies a number of events of default (some of which are subject to applicable cure periods), including (i) failure to cause royalty payments to be deposited into the segregated bank account, (ii) payment defaults, (iii) breaches of representations and warranties made at the time the Notes were issued, (iv) covenant defaults, (v) a final and unappealable judgment against Antigenics for the payment of money in excess of $1.0 million, (vi) bankruptcy or insolvency defaults, (vii) the failure to maintain a first-priority perfected security interest in the Collateral in favor of the collateral agent and (viii) the occurrence of a change of control of Agenus. Upon the occurrence of an event of default, subject to cure periods in certain circumstance and some limited exceptions, Oberland may declare the Notes immediately due and payable, in which case Antigenics would owe a payment equal to the Redemption Payment (the “Accelerated Default Payment”). Upon the occurrence and during the continuance of any event of default, interest on the Notes also increases by 2.5% per annum. Agenus and Aronex (together, the “Guarantors”), are parties to the NPA as guarantors of certain of Antigenics’ obligations under the NPA. The Guarantors generally guarantee the Put Payment, the Make-Whole Payment, the Redemption Payment and the Accelerated Default Payment. In accordance with the guidance of ASC 470-10-25 Debt: Recognition, We will periodically assess the expected royalties using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the estimated time period over which the debt and interest will be repaid. There are a number of factors that could materially affect the amount and timing of royalty payments from GSK, all of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, patent protection, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates, and other events or circumstances that could result in reduced royalty payments from GSK, all of which would result in a reduction of royalty revenues and the interest expense over the life of the NPA. As royalties are remitted to the purchasers, we will record non-cash royalty revenues and non-cash interest expense within our consolidated statements of operations and comprehensive loss over the term of the NPA as interest accrues and royalties are generated. We did not recognize any royalty revenue and recorded $825,000 in non-cash interest expense for the three and nine months-ended September 30, 2015 within our condensed consolidated statement of operations and comprehensive loss. In connection with the execution of the NPA, we reimbursed the purchasers for legal fees of $250,000 and incurred debt issuance costs of approximately $1.5 million. Under the relevant accounting guidance, legal fees and debt issuance costs have been recorded as a reduction to the gross proceeds. These amounts are being amortized over 12 years, the expected term of the Notes, using the effective interest rate method. Other In April 2015, we made our final payment of approximately $278,000 under our $5.0 million Loan and Security Agreement with Silicon Valley Bank (the "SVB Loan") in accordance with the terms of the SVB Loan. We have no further outstanding indebtedness or obligations under the SVB Loan.

Revenue Interest Assignment Ter

Revenue Interest Assignment Termination	9 Months Ended
	Sep. 30, 2015
Contract Termination Claims And Loans [Abstract]
Revenue Interest Assignment Termination	Note F – Revenue Interest Assignment Termination On April 15, 2013, we and Antigenics entered into a Revenue Interests Assignment Agreement (the “Original Agreement”) with Ingalls & Snyder Value Partners, L.P. and Arthur Koenig (together, “Ingalls”), pursuant to which we and Antigenics sold to Ingalls 20% of all the royalties Antigenics was entitled to receive from GSK and Janssen Sciences Ireland Uc on products associated with Agenus’s QS-21 Stimulon (collectively, the “Assigned Interests”). On September 4, 2015, we and Antigenics entered into a Revenue Interest Assignment and Termination Agreement (the “Assignment and Termination Agreement”) with Ingalls, pursuant to which we terminated the Original Agreement and repurchased the Assigned Interests in exchange for (i) $20.0 million in cash and (ii) 300,000 shares of Agenus common stock for total consideration of approximately $22.1 million. The closing under the Assignment and Termination Agreement took place on September 8, 2015 immediately prior to the closing under the NPA. Effective September 8, 2015, we have no further obligations under the Original Agreement. For the three months ended September 30, 2015 we recorded a fair value adjustment of approximately $495,000 upon settlement of the contingent royalty obligation recorded within non-operating (expense) income in our condensed consolidated statement of operations and comprehensive loss.

Accrued and Other Current Liabi

Accrued and Other Current Liabilities	9 Months Ended
	Sep. 30, 2015
Other Liabilities Disclosure [Abstract]
Other Current Liabilities	Note G - Accrued and Other Current Liabilities Accrued liabilities consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September December 31, 2014 Payroll $ 3,592 $ 3,134 Professional fees 3,349 1,438 Contract Manufacturing Costs 2,495 245 License Fees Payable 2,200 — Other 2,103 685 Total $ 13,739 $ 5,502 Other current liabilities consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September December 31, 2014 Current portion of deferred purchase price (Note L) $ 4,933 $ — Other 409 575 Total $ 5,342 $ 575

Collaborations (Notes)

Collaborations (Notes)	9 Months Ended
	Sep. 30, 2015
Collaboration [Abstract]
Collaborations	Note H - Collaborations Incyte Corporation- On January 9, 2015 and effective February 19, 2015, we entered into a global license, development and commercialization agreement (the “Collaboration Agreement”) with Incyte pursuant to which the parties plan to develop and commercialize novel immuno-therapeutics using our proprietary antibody discovery platforms. The Collaboration Agreement is initially focused on four checkpoint modulator programs directed at GITR, OX40, LAG-3 and TIM-3. In addition to the four identified antibody programs, the parties have an option to jointly nominate and pursue the development and commercialization of antibodies against additional targets during a five year discovery period which, upon mutual agreement of the parties for no additional consideration, can be extended for an additional three years. On January 9, 2015 we also entered into a Stock Purchase Agreement with Incyte Corporation (the “Stock Purchase Agreement”) whereby, for an aggregate purchase price of $35.0 million, Incyte purchased approximately 7.76 million shares of our common stock; see Note K for more details. Agreement Structure Under the terms of the Collaboration Agreement, we received a non-creditable, nonrefundable upfront payment of $25.0 million. In addition, the parties will share all costs and profits for the GITR and OX40 antibody programs on a 50:50 basis (profit-share products), and we are eligible to receive up to $20 million in future contingent development milestones under these programs. Incyte is obligated to reimburse us for all development costs that we incur in connection with the TIM-3 and LAG-3 antibody programs (royalty-bearing products) and we are eligible to receive (i) up to $155 million in future contingent development, regulatory, and commercialization milestone payments and (ii) tiered royalties on global net sales at rates generally ranging from 6% to 12%. For each royalty-bearing product, we will also have the right to elect to co-fund 30% of development costs incurred following initiation of pivotal clinical trials in return for an increase in royalty rates. Additionally, we retain co-promotion participation rights in the United States on any profit-share product. Through the direction of a joint steering committee, the parties anticipate that, for each program, we will serve as the lead for pre-clinical development activities through investigational new drug application filing, and Incyte will serve as the lead for clinical development activities. The parties expect to initiate the first clinical trials of antibodies arising from these programs in 2016. For each additional program beyond GITR, OX40, TIM-3 and LAG-3 that the parties elect to bring into the collaboration, if any, we will have the option to designate it as a profit-share product or a royalty-bearing product. The Collaboration Agreement will continue as long as (i) any product is being developed or commercialized or (ii) the discovery period remains in effect. After the first anniversary of the effective date of the Collaboration Agreement, Incyte may terminate the Collaboration Agreement or any individual program for convenience upon 12 months’ notice. The Collaboration Agreement may also be terminated by either party upon the occurrence of an uncured material breach of the other party or by us if Incyte challenges patent rights controlled by us. In addition, either party may terminate the Collaboration Agreement as to any program if the other party is acquired and the acquiring party controls a competing program. Collaboration Revenue For the three and nine months ended September 30, 2015 ,

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	Note I - Fair Value Measurements We measure our short-term investments, contingent purchase price consideration and in the past, our contingent royalty obligation, at fair value. Our short-term investments are comprised solely of U.S. Treasury Bills that are valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level 1 assets. The fair value of our $3.7 million contingent purchase price consideration is based on significant inputs not observable in the market, which require it to be reported as a Level 3 liability within the fair value hierarchy. The valuation of this liability uses assumptions we believe would be made by a market participant. In particular, the fair value of our contingent purchase price consideration is based on estimates from a Monte Carlo simulation of our market capitalization and other factors impacting the probability of triggering the milestone payments. Market capitalization was evolved using a geometric brownian motion, calculated daily for the life of the contingent purchase price consideration. We completed the valuation analysis for the contingent royalty obligation using discounted cash flow based on the sum of the economic income that an asset is anticipated to produce in the future. In this case, that asset was the potential royalty income to be paid to us as a result of certain license agreements for QS-21 Stimulon. The fair value of the contingent royalty obligation was estimated by applying a risk adjusted discount rate (10.2%) to the probability adjusted royalty revenue stream based on expected approval dates. These fair value estimates were most sensitive to changes in the probability of regulatory approvals. Assets and liabilities measured at fair value are summarized below (in thousands): Description September 30, 2015 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Short-term investments $ 14,994 $ 14,994 $ — $ — Liabilities: Contingent purchase price consideration 3,747 — — 3,747 Description December 31, 2014 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Short-term investments $ 14,510 $ 14,510 $ — $ — Liabilities: Contingent royalty obligation 15,279 — — 15,279 Contingent purchase price consideration 16,420 — — 16,420 Total $ 31,699 $ — $ — $ 31,699 The following table presents our liabilities measured at fair value using significant unobservable inputs (Level 3), as of September 30, 2015 (amounts in thousands): Balance, December 31, 2014 $ 31,699 Change in fair value of contingent royalty obligation during the period 6,863 Change in fair value of contingent purchase price consideration during the period 7,327 Payment of contingent purchase price milestone (20,000 ) Settlement of contingent royalty obligation (22,142 ) Balance, September 30, 2015 $ 3,747 The change in fair value of the contingent royalty obligation liability is included in non-operating (expense) income in our condensed consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2015. There were no changes in the valuation techniques during the period and there were no transfers into or out of Levels 1 and 2. On January 23, 2015, we achieved the first contingent milestone pursuant to the terms of our Share Exchange Agreement dated January 10, 2014, by and among us, 4-AB, the former shareholder of 4-AB and Vischer AG, as Representative (the "Share Exchange Agreement"), and accordingly we paid $20.0 million. As outlined in Note F, we settled our contingent royalty obligation owed to Ingalls for consideration of $22.1 million as of the transaction date, which we concluded approximated its fair value. The estimated fair values of all of our financial instruments, excluding our outstanding debt, approximate their carrying amounts in the condensed consolidated balance sheets. The fair value of our outstanding debt was derived by evaluating the nature and terms of each note and considering the prevailing economic and market conditions at the balance sheet date. The fair value of our outstanding debt balance at September 30, 2015 and December 31, 2014 was $116.2 million and $6.1 million, respectively, based on the Level 2 valuation hierarchy of the fair value measurements standard using a present value methodology. The principal amount of our outstanding debt balance at September 30, 2015 and December 31, 2014 was $114.1 million and $6.3 million, respectively.

Share-Based Compensation Plans

Share-Based Compensation Plans (Notes)	9 Months Ended
	Sep. 30, 2015
Share Based Compensation [Abstract]
Share-Based Compensation	Note J - Share-based Compensation Plans We primarily use the Black-Scholes option pricing model to value stock options granted to employees and non-employees, including stock options granted to members of our Board of Directors. All stock options have 10-year terms and generally vest ratably over a 3 or 4-year period. A non-cash charge to operations for the stock options granted to non-employees that have vesting or other performance criteria is affected each reporting period, until the non-employee options vest, by changes in the fair value of our common stock. A summary of option activity for the nine months ended September 30, 2015 is presented below: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in Aggregate Intrinsic Value Outstanding at December 31, 2014 6,525,724 $ 4.40 Granted 2,585,544 5.93 Exercised (458,678 ) 3.83 Forfeited (292,426 ) 3.77 Expired (133,373 ) 9.87 Outstanding at September 30, 2015 8,226,791 7.63 $ 5,965,193 Vested or expected to vest at September 30, 2015 7,522,580 $ 4.79 7.47 $ 5,372,584 Exercisable at September 30, 2015 4,134,451 $ 5.07 6.62 $ 2,825,031 The weighted average grant-date fair values of stock options granted during the nine months ended September 30, 2015 and 2014, were $3.85 and $1.85, respectively. As of September 30, 2015, $8.8 million of total unrecognized compensation cost related to stock options granted to employees and directors is expected to be recognized over a weighted average period of 1.8 years. As of September 30, 2015, unrecognized expense for options granted to outside advisors for which performance (vesting) has not yet been completed but the exercise price of the option is known is $651,000. Such amount is subject to change each reporting period based upon changes in the fair value of our common stock, expected volatility, and the risk-free interest rate, until the outside advisor completes his or her performance under the option agreement. Certain employees and consultants have been granted nonvested stock. The fair value of nonvested stock is calculated based on the closing sale price of our common stock on the date of issuance. A summary of nonvested stock activity for the nine months ended September 30, 2015 is presented below: Nonvested Shares Weighted Average Grant Fair Value Outstanding at December 31, 2014 78,828 $ 3.93 Granted 1,720,430 8.70 Vested (35,332 ) 3.97 Forfeited (29,105 ) 8.57 Outstanding at September 30, 2015 1,734,821 $ 8.58 As of September 30, 2015, there was $11.7 million of unrecognized share-based compensation expense related to these nonvested shares awarded to employees of which $108,000 is expected to be recognized over a weighted average period of 1.4 years. The remaining $11.6 million of unrecognized share-based compensation expense relates to performance based awards for which, if all milestones are achieved, will be recognized over a 3 year period. As of September 30, 2015, unrecognized expense for nonvested shares awarded to outside advisors is $28,000. The total intrinsic value of shares vested during the nine months ended September 30, 2015, was $140,000. During the nine months ended September 30, 2015, 63,539 shares were issued under the 2009 Employee Stock Purchase Plan, 35,332 shares were issued as a result of the vesting of nonvested stock and 458,678 shares were issued as a result of stock option exercises. The impact on our results of operations from share-based compensation for the three and nine months ended September 30, 2015, and 2014, was as follows (in thousands): Three September 30, Nine months ended September 30, 2015 2014 2015 2014 Research and development $ 453 $ 274 $ 1,695 $ 936 General and administrative 320 1,005 3,523 2,765 Total share-based compensation expense $ 773 $ 1,279 $ 5,218 $ 3,701

Equity

Equity	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Equity	Note K - Equity On January 9, 2015, in connection with the execution of the Collaboration Agreement, we also entered into the Stock Purchase Agreement with Incyte Corporation, pursuant to which Incyte purchased approximately 7.76 million shares of our common stock (the “Shares”) in February 2015 for an aggregate purchase price of $35.0 million, or approximately $4.51 per share. Under the Stock Purchase Agreement, Incyte has agreed not to dispose of any of the Shares for a period of 12 months and we agreed to register the Shares for resale under the Securities Act of 1933, as amended (the "Securities Act"). In connection with the achievement of the first contingent milestone pursuant to the Share Exchange Agreement, in March and April 2015, we issued 50,596 shares of our common stock valued at approximately $217,000 and 29,897 shares of our common stock valued at approximately $128,000, respectively, as payment of a portion of our obligation. In April 2015, in accordance with the payment terms of an asset purchase agreement, as detailed in Note L, we issued 574,140 shares of our common stock to the members of Celexion valued at $3.0 million. In May 2015, we issued and sold 12,650,000 shares of our common stock in an underwritten public offering. Net proceeds after deducting offering expenses were approximately $75.0 million.

Asset Purchase Agreement

Asset Purchase Agreement	9 Months Ended
	Sep. 30, 2015
Asset Purchase Agreement [Abstract]
Asset Purchase Agreement	Note L - Asset Purchase Agreement On April 7, 2015 (the “Celexion Closing Date”), we entered into an Asset Purchase Agreement (the "Purchase Agreement") with Celexion and each of the members of Celexion, pursuant to which, we acquired Celexion’s SECANT yeast display antibody discovery platform, its full-length IgG antibody library, its technology for the discovery of molecules targeting cell membrane-associated antigens, and certain other related intellectual property assets (collectively, the “Purchased Assets”). As consideration for the Purchased Assets, on the Celexion Closing Date we paid Celexion $1.0 million in cash and issued Celexion 574,140 shares of our common stock valued at approximately $5.23 per share. As additional consideration for the Purchased Assets, we agreed under the Purchase Agreement to pay to Celexion (i) $1.0 million in cash payable on each of the 9-month and 18-month anniversaries of the Celexion Closing Date and (ii) $4.0 million on each of the 12-month and 24-month anniversaries of the Celexion Closing Date payable at our discretion in cash, shares of our common stock, or any combination thereof. If we elect to pay any of the additional consideration in shares of our common stock, such shares will be issued at a price per share equal to the simple average of the daily closing volume weighted average price over the 20 trading days preceding the date of issuance. We agreed to file one or more registration statements under the Securities Act to cover the resale of all shares issued as consideration under the Purchase Agreement. In May 2015, we filed a registration statement covering the resale of 574,140 shares issued to Celexion, and the SEC declared the registration statement effective in June 2015. This transaction was accounted for as an asset acquisition in accordance with ASC 805 Business Combinations. Research and Development,

Benefit Plans (Notes)

Benefit Plans (Notes)	9 Months Ended
	Sep. 30, 2015
Compensation And Retirement Disclosure [Abstract]
Benefit Plans	Note M - Benefit Plans We maintain a multiple employer benefit plan that covers all of our international employees. The annual measurement date for this plan is December 31. Benefits are based upon years of service and compensation. For the three and nine months ended September 30, 2015 we contributed approximately $26,000 and $80,000, respectively, and for the three and nine months ended September 30, 2014 we contributed approximately $27,000 and $81,000, to our international multiple employer benefit plan. For the remainder of the year ending December 31, 2015 we expect to contribute approximately $24,000 to the plan.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2015
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Accounting Pronouncements	Note N - Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern In April 2015, the FASB issued ASU No. 2015-03, Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, ).

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding	Nine months ended September 30, 2015 2014 Warrants 4,351,450 2,951,450 Stock options 8,226,791 6,841,400 Nonvested shares 1,734,821 78,828 Convertible preferred stock 333,333 333,333

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2015
Investments [Abstract]
Schedule of cash equivalents and short-term investments	Cash equivalents and short-term investments consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Cost Estimated Fair Value Cost Estimated Fair Value Institutional Money Market Funds $ 172,811 $ 172,811 $ 25,149 $ 25,149 U.S. Treasury Bills 14,971 14,994 14,508 14,510 Total $ 187,782 $ 187,805 $ 39,657 $ 39,659

Goodwill and Acquired Intangi23

Goodwill and Acquired Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes in Goodwill	The following table sets forth the changes in the carrying amount of goodwill for the nine months ended September 30, 2015 (in thousands): Balance, December 31, 2014 $ 17,869 Foreign currency translation adjustment 271 Balance, September 30, 2015 $ 18,140
Schedule of Acquired Finite-Lived Intangible Assets	Acquired intangible assets consisted of the following at September 30, 2015 (in thousands): Amortization (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual Property 15 years $ 4,425 $ (479 ) $ 3,946 Trademarks 4.5 years 829 (300 ) 529 Other 3 years 175 (95 ) 80 In-process research and development Indefinite 1,935 — 1,935 Total $ 7,364 $ (874 ) $ 6,490
Schedule of Acquired Indefinite-Lived Intangible Assets	Acquired intangible assets consisted of the following at September 30, 2015 (in thousands): Amortization (years) Gross carrying amount Accumulated amortization Net carrying amount Intellectual Property 15 years $ 4,425 $ (479 ) $ 3,946 Trademarks 4.5 years 829 (300 ) 529 Other 3 years 175 (95 ) 80 In-process research and development Indefinite 1,935 — 1,935 Total $ 7,364 $ (874 ) $ 6,490

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Debt Obligations	Debt obligations consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): Debt instrument Principal at September 30, 2015 Non-cash Interest Unamortized Debt Issuance Costs Unamortized Debt Discount Balance at September 30, 2015 Current Portion: Debentures $ 146 $ — $ — $ — $ 146 Long-term Portion: 2015 Subordinated Notes 14,000 — — (2,510 ) 11,490 Note Purchase Agreement 100,000 825 (1,514 ) (248 ) 99,063 Total long-term $ 114,000 $ 825 $ (1,514 ) $ (2,758 ) $ 110,553 Total $ 114,146 $ 825 $ (1,514 ) $ (2,758 ) $ 110,699 Debt instrument Principal at December 31, 2014 Non-cash Interest Unamortized Debt Issuance Costs Unamortized Debt Discount Balance at December 31, 2014 Current Portion: Debentures $ 146 $ — $ — $ — $ 146 SVB Loan 1,111 — — — 1,111 Total current $ 1,257 $ — $ — $ — $ 1,257 Long-term Portion: 2013 Notes 5,000 — — (231 ) 4,769 Total $ 6,257 $ — $ — $ (231 ) $ 6,026

Accrued and Other Current Lia25

Accrued and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Other Liabilities Disclosure [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September December 31, 2014 Payroll $ 3,592 $ 3,134 Professional fees 3,349 1,438 Contract Manufacturing Costs 2,495 245 License Fees Payable 2,200 — Other 2,103 685 Total $ 13,739 $ 5,502
Other Current Liabilities	Other current liabilities consisted of the following as of September 30, 2015 and December 31, 2014 (in thousands): September December 31, 2014 Current portion of deferred purchase price (Note L) $ 4,933 $ — Other 409 575 Total $ 5,342 $ 575

Fair Value Measurements Fair va

Fair Value Measurements Fair value measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured at fair value are summarized below (in thousands): Description September 30, 2015 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Short-term investments $ 14,994 $ 14,994 $ — $ — Liabilities: Contingent purchase price consideration 3,747 — — 3,747 Description December 31, 2014 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Short-term investments $ 14,510 $ 14,510 $ — $ — Liabilities: Contingent royalty obligation 15,279 — — 15,279 Contingent purchase price consideration 16,420 — — 16,420 Total $ 31,699 $ — $ — $ 31,699
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table presents our liabilities measured at fair value using significant unobservable inputs (Level 3), as of September 30, 2015 (amounts in thousands): Balance, December 31, 2014 $ 31,699 Change in fair value of contingent royalty obligation during the period 6,863 Change in fair value of contingent purchase price consideration during the period 7,327 Payment of contingent purchase price milestone (20,000 ) Settlement of contingent royalty obligation (22,142 ) Balance, September 30, 2015 $ 3,747

Share-Based Compensation Plan27

Share-Based Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Share Based Compensation [Abstract]
Schedule Of Stock Option Activity	A summary of option activity for the nine months ended September 30, 2015 is presented below: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in Aggregate Intrinsic Value Outstanding at December 31, 2014 6,525,724 $ 4.40 Granted 2,585,544 5.93 Exercised (458,678 ) 3.83 Forfeited (292,426 ) 3.77 Expired (133,373 ) 9.87 Outstanding at September 30, 2015 8,226,791 7.63 $ 5,965,193 Vested or expected to vest at September 30, 2015 7,522,580 $ 4.79 7.47 $ 5,372,584 Exercisable at September 30, 2015 4,134,451 $ 5.07 6.62 $ 2,825,031
Schedule Of Nonvested Shares	A summary of nonvested stock activity for the nine months ended September 30, 2015 is presented below: Nonvested Shares Weighted Average Grant Fair Value Outstanding at December 31, 2014 78,828 $ 3.93 Granted 1,720,430 8.70 Vested (35,332 ) 3.97 Forfeited (29,105 ) 8.57 Outstanding at September 30, 2015 1,734,821 $ 8.58
Schedule Of Share-Based Compensation Expense	The impact on our results of operations from share-based compensation for the three and nine months ended September 30, 2015, and 2014, was as follows (in thousands): Three September 30, Nine months ended September 30, 2015 2014 2015 2014 Research and development $ 453 $ 274 $ 1,695 $ 936 General and administrative 320 1,005 3,523 2,765 Total share-based compensation expense $ 773 $ 1,279 $ 5,218 $ 3,701

Disclosure - Business, Liquidit

Disclosure - Business, Liquidity and Basis of Presentation (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Description Of Business [Abstract]
Proceeds from future royalties received	$ 98,200,000
Accumulated deficit	$ (763,580,441)	$ (691,306,343)

Net Loss Per Share - Anti-dilut

Net Loss Per Share - Anti-dilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,351,450	2,951,450
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,226,791	6,841,400
Nonvested shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,734,821	78,828
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	333,333	333,333

Investments (Details)

Investments (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Cash Equivalents, at Carrying Value	$ 172,800,000	$ 25,100,000
Short-term investments	14,993,700	14,509,570
Cost [Member]
Cash equivalents and short-term investments	187,782,000	39,657,000
Estimate of Fair Value [Member]
Cash equivalents and short-term investments	187,805,000	39,659,000
Money Market Funds [Member] | Cost [Member]
Cash Equivalents, at Carrying Value	172,811,000	25,149,000
Money Market Funds [Member] | Estimate of Fair Value [Member]
Cash Equivalents, at Carrying Value	172,811,000	25,149,000
US Treasury Bills [Member] | Cost [Member]
Short-term investments	14,971,000	14,508,000
US Treasury Bills [Member] | Estimate of Fair Value [Member]
Short-term investments	$ 14,994,000	$ 14,510,000

Investments (Narrative) (Detail

Investments (Narrative) (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Investments [Abstract]
Proceeds from sale of available-for-sale securities	$ 14,534,486	$ 0	$ 0
Cash equivalents	172,800,000		25,100,000
Short-term investments	$ 14,993,700		$ 14,509,570

Goodwill and Acquired Intangi32

Goodwill and Acquired Intangible Assets (Schedule of Changes in Goodwill) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 17,869,023
Foreign currency translation adjustment	271,000
Ending balance	$ 18,139,991

Goodwill and Acquired Intangi33

Goodwill and Acquired Intangible Assets (Acquired Finite-Lived Intangible Assets) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (873,667)	$ (462,248)
Indefinite-lived Intangible Assets Acquired	1,935,000
Intangible Assets, Gross (Excluding Goodwill)	7,364,000
Net carrying amount	$ 6,490,481	$ 6,773,722
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	15 years
Gross carrying amount	$ 4,425,000
Accumulated Amortization	(479,000)
Net carrying amount	$ 3,946,000
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	4 years 6 months
Gross carrying amount	$ 829,000
Accumulated Amortization	(300,000)
Net carrying amount	$ 529,000
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization period (years)	3 years
Gross carrying amount	$ 175,000
Accumulated Amortization	(95,000)
Net carrying amount	$ 80,000

Goodwill and Acquired Intangi34

Goodwill and Acquired Intangible Assets (Narrative) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	13 years
Finite-Lived Intangible Assets, Estimated Amortization Expense, Remainder of 2015	$ 134,000
Finite-Lived Intangible Assets, Estimated Amortization Expense, 2016	512,000
Finite-Lived Intangible Assets, Estimated Amortization Expense, 2017	512,000
Finite-Lived Intangible Assets, Estimated Amortization Expense, 2018	410,000
Finite-Lived Intangible Assets, Estimated Amortization Expense, 2019	295,000
Finite-Lived Intangible Assets, Estimated Amortization Expense, 2020 -2029	$ 299,000

Debt - Schedule of Debt Obligat

Debt - Schedule of Debt Obligations (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Feb. 20, 2015	Dec. 31, 2014
Debt instrument, Current Portion
Debt Instrument Principal, Current Portion				$ 1,257,000
Balance, Current Portion	$ 146,061	$ 146,061		1,257,178
Debt instrument, Long-term Portion
Principal Balance, Long-term Portion	114,000,000	114,000,000
Non-cash Interest		825,000
Unamortized Debt Issuance Costs, Long-term Portion	(1,514,000)	(1,514,000)
Unamortized Debt Discount, Long-term Portion	(2,758,000)	(2,758,000)	$ (3,000,000)
Balance, Long-term Portion	110,553,452	110,553,452		4,769,359
Principal, Balance Total	114,146,000	114,146,000		6,257,000
Non-cash Interest Total		825,000
Unamortized Debt Issuance Costs Total	(1,514,000)	(1,514,000)
Unamortized Debt Discount Total	(2,758,000)	(2,758,000)		(231,000)
Balance, Long-Term Debt Total	110,699,000	110,699,000		6,026,000
2015 Subordinated Notes [Member]
Debt instrument, Long-term Portion
Principal Balance, Long-term Portion	14,000,000	14,000,000
Unamortized Debt Discount, Long-term Portion	(2,510,000)	(2,510,000)
Balance, Long-term Portion	11,490,000	11,490,000
Note Purchase Agreement [Member]
Debt instrument, Long-term Portion
Principal Balance, Long-term Portion	100,000,000	100,000,000
Non-cash Interest	825,000	825,000
Unamortized Debt Issuance Costs, Long-term Portion	(1,514,000)	(1,514,000)
Unamortized Debt Discount, Long-term Portion	(248,000)	(248,000)
Balance, Long-term Portion	99,063,000	99,063,000
2013 Notes [Member]
Debt instrument, Long-term Portion
Principal Balance, Long-term Portion				5,000,000
Unamortized Debt Discount, Long-term Portion				(231,000)
Balance, Long-term Portion				4,769,359
Debentures [Member]
Debt instrument, Current Portion
Debt Instrument Principal, Current Portion	146,000	146,000		146,000
Balance, Current Portion	$ 146,000	$ 146,000		146,000
SVB Loan [Member]
Debt instrument, Current Portion
Debt Instrument Principal, Current Portion				1,111,000
Balance, Current Portion				$ 1,111,000

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($)	Sep. 08, 2015	Feb. 20, 2015	Apr. 30, 2015	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.10
Loss on extinguishment of debt					$ (154,117)	$ 0
Debt Instrument, Unamortized Discount		$ 3,000,000		$ 2,758,000	2,758,000
Debt Instrument, Convertible, Remaining Discount Amortization Period		3 years
Noncash interest expenses					825,000
Debt issuance costs				1,500,000
Outstanding Indebtedness or Obligations				$ 110,699,000	$ 110,699,000		$ 6,026,000
Antigenics LLC [Member]
Debt Instrument [Line Items]
Maximum repurchase percentage of notes				15.00%	15.00%
Maximum period for repurchase of notes					90 days
Amounts payable to purchasers on maturity date				$ 100,000,000	$ 100,000,000
Additional amount payable in issuance of excess of notes on maturity date				115,000,000	115,000,000
Notes default payment amount				$ 1,000,000	$ 1,000,000
Increase in interest rate on notes in event of default				2.50%	2.50%
Antigenics LLC [Member] | Within 24 Months of the Closing Date [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage					20.00%
Antigenics LLC [Member] | After 24 Months but Within 48 Months of the Closing Date [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage					17.50%
Antigenics LLC [Member] | More than 48 Months After the Closing Date [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage					15.00%
Common Stock [Member]
Debt Instrument [Line Items]
warrants issued		1,400,000
Limited Recourse Notes [Member] | Antigenics LLC [Member] | Oberland Capital SA Zermatt LLC [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 100,000,000
Additional notes maximum issuance period	15 days
Debt instrument accrued interest rate percentage				13.50%	13.50%
Debt instrument period for computation of interest rate					360 days
Additional Notes [Member] | Antigenics LLC [Member] | Oberland Capital SA Zermatt LLC [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 15,000,000
SVB Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 5,000,000
Debt Instrument, Periodic Payment, Principal			278,000
Outstanding Indebtedness or Obligations			$ 0
Senior Subordinated Notes [Member] | Notes 2013 Exchanged To Notes 2015 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 5,000,000
Senior Subordinated Notes [Member] | Notes 2015 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 9,000,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Debt Default Provisions, Face Amount		$ 13,500,000
Debt Instrument, Maturity Date					Feb. 20, 2018
Note Purchase Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount				$ 248,000	$ 248,000
Debt Instrument, Convertible, Remaining Discount Amortization Period					12 years
Noncash interest expenses				825,000	$ 825,000
Royalty revenue recognized				$ 0	0
Reimbursed purchaser for legal fees					250,000
Debt issuance costs					$ 1,500,000

Revenue Interest Assignment T37

Revenue Interest Assignment Termination (Narrative) (Details) - USD ($)	Sep. 04, 2015	May. 31, 2015	Sep. 30, 2015	Apr. 15, 2013
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Stock issued to repurchase the Assigned Interest		12,650,000
Assignment and Termination Agreement [Member]
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
Percent of royalties sold under repurchase agreement				20.00%
Cash payment to repurchase the Assigned Interest	$ 20,000,000
Stock issued to repurchase the Assigned Interest	300,000
Total consideration amount to repurchase the Assigned Interest	$ 22,100,000
Fair value adjustment settlement amount of contingent royalty			$ 495,000

Accrued and Other Current Lia38

Accrued and Other Current Liabilities Schedule of accrued liabilities (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities Current [Abstract]
Accrued Salaries, Current	$ 3,592,000	$ 3,134,000
Accrued Professional Fees, Current	3,349,000	1,438,000
Accrued contract manufacturing costs	2,495,000	245,000
Accrued License Fees Payable, Current	2,200,000	0
Other Accrued Liabilities, Current	2,103,000	685,000
Total	$ 13,738,916	$ 5,501,527

Schedule of Other Current Liabi

Schedule of Other Current Liabilities (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Current portion purchase price	$ 4,933,000	$ 0
Other, current	409,000	575,000
Total	$ 5,342,496	$ 575,351

Collaborations (Narrative) (Det

Collaborations (Narrative) (Details)	Sep. 04, 2015shares	Feb. 19, 2015USD ($)Programshares	Jan. 09, 2015USD ($)	May. 31, 2015USD ($)shares	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from Issuance of Common Stock				$ 75,000,000
Stock issued to repurchase the Assigned Interest | shares				12,650,000
Revenues					$ 6,848,194	$ 1,563,378	$ 17,178,191	$ 5,358,322
Deferred Revenue, Current					5,967,198		5,967,198		$ 184,421
Deferred Revenue, Noncurrent					15,498,207		15,498,207		$ 3,009,568
Profit-share products [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone Payments for License Costs			$ 20,000,000
Royalty-bearing products [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone Payments for License Costs			$ 155,000,000
Stock Purchase Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from Issuance of Common Stock		$ 35,000,000
Stock issued to repurchase the Assigned Interest | shares		7,760,000
Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Stock issued to repurchase the Assigned Interest | shares	300,000
Percentage of profit and costs sharing ratio			50.00%
Revenues					6,500,000		16,100,000
Revenue, amortization					2,600,000		$ 6,600,000
Development Regulatory and Commercialization Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Reserved right to elect to co-fund of development costs (as a percent)			30.00%
Development Regulatory and Commercialization Milestones [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Range of royalty payments on future global net sales (as a percent)			6.00%
Development Regulatory and Commercialization Milestones [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Range of royalty payments on future global net sales (as a percent)			12.00%
Incyte [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of collaboration agreement programs | Program		4
Discovery period of antibodies development and commercialization period		5 years
Extended discovery period of antibodies development and commercialization period		3 years
Collaboration agreement termination notice period							12 months
Deferred Revenue					18,400,000		$ 18,400,000
Deferred Revenue, Current					5,800,000		5,800,000
Deferred Revenue, Noncurrent					$ 12,600,000		$ 12,600,000
Incyte [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from Collaborators			$ 25,000,000

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase price consideration	$ 3,747	$ 16,420
Fair Value Inputs, Discount Rate	10.20%
Long-term Debt, Gross	$ 114,146	6,257
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase price consideration	3,747	16,420
Fair Value, Inputs, Level 3 [Member] | Contingent purchase price [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment of contingent consideration	20,000
Fair Value, Inputs, Level 3 [Member] | Contingent royalty consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payment of contingent consideration	22,142
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent purchase price consideration	0	0
Debt Instrument, Fair Value Disclosure	$ 116,200	$ 6,100

Fair Value Measurements Asset a

Fair Value Measurements Asset and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure	$ 14,994	$ 14,510
Purchase Price Consideration, Fair Value Disclosure	3,747	16,420
Obligations, Fair Value Disclosure		15,279
Total		31,699
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure	14,994	14,510
Purchase Price Consideration, Fair Value Disclosure	0	0
Obligations, Fair Value Disclosure		0
Total		0
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure	0	0
Purchase Price Consideration, Fair Value Disclosure	0	0
Obligations, Fair Value Disclosure		0
Total		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments, Fair Value Disclosure	0	0
Purchase Price Consideration, Fair Value Disclosure	$ 3,747	16,420
Obligations, Fair Value Disclosure		15,279
Total		$ 31,699

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Balance, beginning of period	$ 31,699
Balance, end of period	3,747
Contingent royalty consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value during period	6,863
Settlement	(22,142)
Contingent purchase price [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value during period	7,327
Settlement	$ (20,000)

Share-Based Compensation Plan44

Share-Based Compensation Plans (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Weighted average grant-date fair value of options granted	$ 3.85	$ 1.85
Employee nonvested shares excepted to be recognized	$ 108,000
Intrinsic value of shares vested	$ 140,000
Vesting of nonvested shares, shares	35,332
Shares issued from exercise of options	458,678
Employees and directors [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 8,800,000
Consultant [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	651,000
Outside Advisors [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 28,000
Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost, weighted average period	1 year 9 months 18 days
Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 11,700,000
Unrecognized compensation cost, weighted average period	1 year 4 months 24 days
Performance Based Award [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Unrecognized compensation cost, weighted average period	3 years
Remaining unrecognized share-based compensation expense	$ 11,600,000
2009 EIP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Deferred Compensation Arrangement with Individual, Maximum Contractual Term	10 years
2009 ESPP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares issued under ESPP	63,539
Minimum [Member] | 2009 EIP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period, minimum	3 years
Maximum [Member] | 2009 EIP [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Vesting period, minimum	4 years

Share-Based Compensation Plan45

Share-Based Compensation Plans (Schedule Of Stock Option Activity) (Details)	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share Based Compensation [Abstract]
Options outstanding, beginning balance	6,525,724
Options granted	2,585,544
Options exercised	(458,678)
Options forfeited	(292,426)
Options expired	(133,373)
Options outstanding, ending balance	8,226,791
Options vested or expected to vest	7,522,580
Options exercisable	4,134,451
Options outstanding, weighted average exercise price, beginning balance | $ / shares	$ 4.40
Options granted, weighted average exercise price | $ / shares	5.93
Options exercised, weighted average exercise price | $ / shares	3.83
Options forfeited, weighted average exercise price | $ / shares	3.77
Options expired, weighted average exercise price | $ / shares	9.87
Options vested or expected to vest, weighted average exercise price | $ / shares	4.79
Options exercisable, weighted average exercise price | $ / shares	$ 5.07
Options outstanding, weighted average remaining contractual term	7 years 7 months 17 days
Options vested or expected to vest, weighted average remaining contractual term	7 years 5 months 19 days
Options exercisable, weighted average remaining contractual term	6 years 7 months 13 days
Options outstanding, aggregate intrinsic value | $	$ 5,965,193
Options vested or expected to vest, aggregate intrinsic value | $	5,372,584
Options exercisable, aggregate intrinsic value | $	$ 2,825,031

Share-Based Compensation Plan46

Share-Based Compensation Plans (Summary Of Nonvested Stock Activity) (Details)	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Share Based Compensation [Abstract]
Nonvested shares outstanding, beginning balance	78,828
Nonvested shares granted	1,720,430
Nonvested shares vested	(35,332)
Nonvested shares forfeited	(29,105)
Nonvested shares outstanding, ending balance	1,734,821
Nonvested shares outstanding, weighted average grant date fair value, beginning balance | $ / shares	$ 3.93
Nonvested shares granted, weighted average grant date fair value | $ / shares	8.70
Nonvested shares vested, weighted average grant date fair value | $ / shares	3.97
Nonvested shares forfeited in Period, Weighted Average Grant Date Fair Value | $ / shares	8.57
Nonvested shares outstanding, weighted average grant date fair value, ending balance | $ / shares	$ 8.58

Share-Based Compensation Plan47

Share-Based Compensation Plans (Schedule Of Share-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 773	$ 1,279	$ 5,218	$ 3,701
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	453	274	1,695	936
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 320	$ 1,005	$ 3,523	$ 2,765

Equity (Narrative) (Details)

Equity (Narrative) (Details) - USD ($)	Apr. 07, 2015	Feb. 19, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Class Of Stock [Line Items]
Stock issued to repurchase the Assigned Interest			12,650,000
Proceeds from Issuance of Common Stock			$ 75,000,000
Shares issued for contingent milestone payment				29,897	50,596
Shares issued for contingent milestone payment, value				$ 128,000	$ 217,000
Stock Issued During Period, Shares, Purchase of Assets	574,140
Stock Issued During Period, Price Per Share	$ 3,000,000
Common stock, shares issued						84,646,215	62,720,065
Common stock, value, outstanding						$ 846,462	$ 627,201
Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Stock issued to repurchase the Assigned Interest		7,760,000
Proceeds from Issuance of Common Stock		$ 35,000,000
Share Price		$ 4.51
Revenue Interest Assignment Termination Agreement
Class Of Stock [Line Items]
Common stock, shares issued						300,000
Common stock, value, outstanding						$ 2,100,000

Asset Purchase Agreement (Narra

Asset Purchase Agreement (Narrative) (Details) - USD ($)	Apr. 07, 2015	May. 31, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]
Shares issued for purchased assets	574,140
Research and development expense			$ 18,502,063	$ 5,284,607	$ 52,495,316	$ 14,979,844
Celexion, LLC [Member]
Finite-Lived Intangible Assets [Line Items]
Cash consideration for purchased assets	$ 1,000,000
Shares issued for purchased assets	574,140	574,140
Shares issued for purchased assets (in US$ per share)	$ 5.23
Research and development expense			$ 0		$ 13,200,000
Asset Purchase Agreement Payable On Nine Month Anniversaries | Celexion, LLC [Member]
Finite-Lived Intangible Assets [Line Items]
Contractual cash payment	$ 1,000,000
Asset Purchase Agreement Payable On Eighteen Month Anniversaries | Celexion, LLC [Member]
Finite-Lived Intangible Assets [Line Items]
Contractual cash payment	1,000,000
Asset Purchase Agreement Payable On Twelve Month Anniversaries | Celexion, LLC [Member]
Finite-Lived Intangible Assets [Line Items]
Contractual cash payment	4,000,000
Asset Purchase Agreement Payable On Twenty Four Month Anniversaries | Celexion, LLC [Member]
Finite-Lived Intangible Assets [Line Items]
Contractual cash payment	$ 4,000,000

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details) - Foreign Postretirement Benefit Plan, Defined Benefit [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer	$ 26,000	$ 27,000	$ 80,000	$ 81,000
Defined Benefit Plans, Estimated Future Employer Contributions in Next Fiscal Year			$ 24,000

Recent Accounting Pronounceme51

Recent Accounting Pronouncements (Narrative) (Details) $ in Millions	3 Months Ended
	Sep. 30, 2015USD ($)
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Debt issuance costs	$ 1.5